Cargando…

Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer

SIMPLE SUMMARY: There is no established standard second-line chemotherapy after modified FOLFIRINOX for unresectable pancreatic cancer. While gemcitabine plus nab-paclitaxel is often used as second-line chemotherapy after modified FOLFIRINOX, outcomes and prognostic factors of second-line gemcitabin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mie, Takafumi, Sasaki, Takashi, Takeda, Tsuyoshi, Okamoto, Takeshi, Hamada, Tsuyoshi, Ishitsuka, Takahiro, Yamada, Manabu, Nakagawa, Hiroki, Furukawa, Takaaki, Kasuga, Akiyoshi, Matsuyama, Masato, Ozaka, Masato, Sasahira, Naoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857205/ https://www.ncbi.nlm.nih.gov/pubmed/36672308 http://dx.doi.org/10.3390/cancers15020358

Ejemplares similares

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
por: Sawada, Masashi, et al.
Publicado: (2020)

Outcomes of Intraductal Placement of Covered Metal Stents for Unresectable Distal Malignant Biliary Obstruction
por: Yamada, Manabu, et al.
Publicado: (2023)

The efficacy and safety of a duckbill‐type anti‐reflux metal stent as the initial metal stent for distal malignant biliary obstruction in unresectable pancreatic cancer
por: Takeda, Tsuyoshi, et al.
Publicado: (2023)

Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer
por: Kasuga, Akiyoshi, et al.
Publicado: (2022)

Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia
por: Takeda, Tsuyoshi, et al.
Publicado: (2022)

Diagnostic yield of endoscopic ultrasound-guided tissue acquisition for small solid pancreatic lesions
por: Mie, Takafumi, et al.
Publicado: (2020)

Novel risk factors for recurrent biliary obstruction and pancreatitis after metallic stent placement in pancreatic cancer
por: Takeda, Tsuyoshi, et al.
Publicado: (2020)

Diagnostic yield of endoscopic ultrasound-guided tissue acquisition for small solid pancreatic lesions
por: Mie, Takafumi, et al.
Publicado: (2020)

Comparison of Endoscopic Ultrasound-Guided Tissue Acquisition Using a 20-Gauge Menghini Needle with a Lateral Forward Bevel and a 22-Gauge Franseen Needle: A Single-Center Large Cohort Study
por: Mie, Takafumi, et al.
Publicado: (2021)

Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients
por: Okamoto, Takeshi, et al.
Publicado: (2023)

Comparison of tube-assisted mapping biopsy with digital single-operator peroral cholangioscopy for preoperative evaluation of biliary tract cancer
por: Takeda, Tsuyoshi, et al.
Publicado: (2022)

Endoscopic Transluminal Stent Placement for Malignant Afferent Loop Obstruction
por: Yonekura, Chinatsu, et al.
Publicado: (2022)

Ruptured cystic artery pseudoaneurysm after self‐expandable metal stent placement for malignant biliary obstruction
por: Mie, Takafumi, et al.
Publicado: (2023)

Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer
por: Yamada, Yuto, et al.
Publicado: (2022)

Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
por: Mita, Naoki, et al.
Publicado: (2019)

Pancreatic follicular lymphoma: a report of two cases and literature review
por: Okamoto, Takeshi, et al.
Publicado: (2021)

Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer
por: Kasuga, Akiyoshi, et al.
Publicado: (2022)

Removal of Duckbill‐type laser‐cut anti‐reflux metal stents: Clinical evaluation and in vitro study
por: Yamada, Yuto, et al.
Publicado: (2023)

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
por: Vogl, Ursula M., et al.
Publicado: (2019)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Successful removal of a biliary metal stent using the stent-in-stent-in-stent technique
por: Matsuyama, Masato, et al.
Publicado: (2023)

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
por: Shirakawa, Tsuyoshi, et al.
Publicado: (2023)

Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy
por: Ito, Genta, et al.
Publicado: (2021)

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
por: Kunzmann, Volker, et al.
Publicado: (2014)

Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer
por: Hino, Kaori, et al.
Publicado: (2022)

Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2022)

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
por: Fukahori, Masaru, et al.
Publicado: (2023)

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
por: Chae, Heejung, et al.
Publicado: (2020)

Results of a single-arm pilot study of (32)P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy
por: Ross, P.J., et al.
Publicado: (2021)

Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)
por: Shibuki, Taro, et al.
Publicado: (2022)

FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
por: Cho, In Rae, et al.
Publicado: (2020)

Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
por: Williet, Nicolas, et al.
Publicado: (2021)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
por: Portal, Alix, et al.
Publicado: (2015)

Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure
por: Hahn, Sarah, et al.
Publicado: (2017)

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
por: Klein-Brill, Avital, et al.
Publicado: (2022)

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
por: Di Costanzo, Francesco, et al.
Publicado: (2023)

Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy
por: Tong, Yi Tat, et al.
Publicado: (2023)

Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution
por: Quan, Qi, et al.
Publicado: (2020)

Comment on: ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'
por: Vivaldi, Caterina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_32vkl8ln8tfr06nuaebt096a16